CYP-LAD, also known as 6-cyclopropyl-6-nor-lysergic acid diethylamide or as TRALA-22, is a lysergamide and analogue of lysergic acid diethylamide (LSD).[1] It was patented by Daniel Trachsel and colleagues in 2023 as an LSD analogue with modified LSD-like action,[1] and had also previously been claimed in a 2022 patent by Gilgamesh Pharmaceuticals.[2]

See also

References

  1. 1 2 US 2023/0414583, Trachsel D, Liechti ME, Lustenberger F, "Lysergic acid derivatives with modified LSD-like action", published 28 December 2023, assigned to Mind Medicine Inc.
  2. ↑ Kruegel AC. Novel Ergolines and Methods of Treating Mood Disorders. Patent WO 2022/226408
source: https://en.wikipedia.org/wiki/CYP-LAD